Sillajen explains Pexa-Vec trial failure – it was the rescue medsSouth Korean biotech Sillajen was hit hard last week when its oncolytic virus therapy Pexa-Vec failed a phase Share XSillajen explains Pexa-Vec trial failure – it was the rescue medshttps://pharmaphorum.com/news/sillajen-explains-pexa-vec-trial-failure-it-was-the-rescue-meds/
Transgene begins trials of head and neck cancer vaccineVirus-based immunotherapy biotech Transgene is to begin clinical trials of its head and neck cancer drug candidate TG4050 Share XTransgene begins trials of head and neck cancer vaccinehttps://pharmaphorum.com/news/transgene-begins-trials-of-head-and-neck-cancer-vaccine/
